Yale University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Yale University sits in the top decile of US sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count).
Yale University: 1,492 sponsored US clinical trials, 254 recruiting.
Yale University sponsors 1,492 registered US clinical trials on ClinicalTrials.gov, 254 of them currently recruiting, and 1,005 completed. 99 of these trials are in Phase 3-4 (later-stage) and 579 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Use Disorder, with 19 trials.
Top-decile sponsor footprint
Yale University ranks in the top decile of sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,005 of 1,138 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,492 total, page 29 of 30
Therapeutic Substance Abuse Treatment in Pregnancy - 1
NCT00227903
Effect of Progesterone on Smoking Behavior in Male and Female Smokers
NCT00271206
Brief Introductory Therapy for Opioid Dependence
NCT00406484
The Effects of GABA Enhancing Medications on Individuals Addicted to Cocaine - 3
NCT00142883
Stage I Randomized Trial of Mentalization-Based Therapy for Substance Using Mothers of Infants and Toddlers
NCT00319436
Usefulness of Selegiline as an Aid to Quit Smoking - 1
NCT00129311
Wait and See Antibiotic Prescription for Acute Otitis Media: A Randomized Controlled Trial
NCT00250900
Directly Observed Therapy for Community-Released HIV+ Prisoners
NCT00786396
Clinical Trial of Abstinence-Linked Money Management
NCT00536900
Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients
NCT00342563
Metabolic Effect of Metformin in Obese Insulin Resistant Adolescents With Normal Glucose Tolerance
NCT00667498
RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders
NCT00080145
Aripiprazole Treatment of Prodromal Patients
NCT00237874
Efficacy of Pimozide Augmentation for Clozapine Partial Response
NCT00374244
Motivational Enhancement for Spanish Speaking Individuals - 1
NCT00078169
Prospective Cohort of Opiate Dependent Patients on Buprenorphine/Naloxone for Maintenance
NCT00622596
Clinical Efficacy of Disulfiram in LAAM-Maintained Cocaine Abusers
NCT00580827
Increasing Treatment Adherence in Co-Occurring Psychiatric and Drug Use Disorders
NCT00237822
Impact of Diet and/or Exercise-induced Weight Loss on Cardiovascular Risk Factors
NCT00588978
Enhancing the Prospective Prediction of Psychosis
NCT00291200
Social Skills in Children With Autism Spectrum Disorders
NCT02147236
Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism
NCT00338598
Long-term Nutritional Intervention Study to Determine How Protein Affects Calcium Metabolism
NCT00671944
Hepatitis B Vaccination Through Syringe Exchange Programs: A Randomized, Controlled Trial of Vaccination Schedules
NCT01259453
HIV Risk Reduction and Drug Abuse Treatment in Malaysia
NCT00383045
Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline)
NCT00000451
Nicotinic Receptor Augmentation of SSRI Antidepressants
NCT00319319
Nicotinic Modulation of Schizophrenia-like Information Processing Deficits in Healthy Subjects
NCT00690170
D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia
NCT00237809
Genetic Counseling for Menopausal Therapy Decision-Making for Women at Increased Risk for Breast Cancer
NCT00349011
Combination Nicotine Replacement for Alcoholic Smokers
NCT00064844
Transcranial Magnetic Stimulation (TMS) Treatment for Patients With Persistent Auditory Hallucinations
NCT00042159
Treatment for Obesity and Binge Eating Disorder
NCT00537758
Emergency Physician Brief Interventions for Alcohol
NCT00443183
Effects of a Comprehensive Weight Management Program on Obese Adolescents and Children
NCT00409422
Treatment of Refractory Schizophrenia With Riluzole
NCT00375050
Environmental Treatment for Seasonal Affective Disorder (SAD)
NCT00139997
C-reactive Protein and Endothelial Dysfunction in Women With Glucose Intolerance
NCT00589355
Gender Differences in Prevalence of Undiagnosed Diabetes in ACS
NCT00589459
Naltrexone & SSRI in Alcoholics With Depression/PTSD
NCT00338962
Antidepressant Treatment for Premenstrual Syndrome and Premenstrual Dysphoric Disorder
NCT00048854
Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth
NCT00536250
Investigation Into the Effects Upon Brain Response to Change in Circulating Glucose Levels in Diabetes Mellitus
NCT00580710
Anger Control Training for Youth With Tourette Syndrome
NCT00486551
Directly Observed Antiretroviral Therapy Among Active Drug Users
NCT00367172
Motivational Enhancement to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse - 1
NCT00032981
Group Prenatal Care for Reducing the Risk of STDs in Pregnant Young Women
NCT00271960
Motivational Interviewing to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse - 1
NCT00032994
Ketamine/Placebo Family History Positive Study
NCT00588952
Intravenous Alcohol Administration Using BrAc Method in Healthy Subjects With and Without a Family History of Alcoholism
NCT00612352
What is open in the Yale University pipeline
254 recruiting of 1,492 indexed (17% open); 1,005 completed (67%).
Phase mix: 99 late (III/IV) vs 579 early (I/II) (early-phase heavy).
Top condition: Opioid Use Disorder (19 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Yale University: open-pipeline peers nationwide
Peers matched on 1,492 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,492 trials (± recruiting share)
- Washington University School of Medicine · 1,502 trials · 14% recruiting
- Johns Hopkins University · 1,448 trials · 17% recruiting
- University of Pennsylvania · 1,423 trials · 14% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
Sponsors near 17% open enrollment (± trial volume)
- NYU Langone Health · 17% recruiting · 1,164 trials
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
Related
What to do with this Yale University page
1,492 registered trials is a research-attention snapshot, not an endorsement of Yale University or any single study.
- 254 of Yale University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Opioid Use Disorder is the condition Yale University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Use Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Yale University pipeline card: 1,492 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.